Dermata Therapeutics Inc (DRMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.06M
Last updated: Nov 17, 2026 at 11:01 AM ET
Dermata Therapeutics Inc (DRMA) Stock Forecast
Analysts expect Dermata Therapeutics (DRMA) to earn -$2.17 per share in the fiscal year ending Dec 31, 2026, on revenue of $100000. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.43.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 650.0%.
- Fiscal year ending Dec 31, 2026
- -$2.17
- EPS consensus, revenue $100000
- Fiscal year ending Dec 31, 2027
- -$1.43
- EPS consensus, revenue $750000
- Next report
- Mar 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.17 | -$2.17 to -$2.17 | 1 | $100000 | $100000 to $100000 | 1 |
| Dec 31, 2027 | -$1.43 | -$1.43 to -$1.43 | 1 | $750000 | $750000 to $750000 | 1 |
Quarterly Estimates
The EPS consensus rises from -$0.47 for the quarter ending Dec 31, 2026 to -$0.42 for the quarter ending Mar 31, 2027.
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.47 | N/A | 3 | $76500 | $73500 to $78750 | 3 |
| Mar 31, 2027 | -$0.42 | -$0.42 to -$0.42 | 1 | $100000 | $100000 to $100000 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.20.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.17 | -$2.21 | -$2.21 | -$2.21 | -$2.20 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.43 | -$1.52 | -$1.52 | -$1.52 | -$1.49 | N/A |
Frequently Asked Questions About DRMA
What is the DRMA stock forecast?
Consensus analyst estimates put Dermata Therapeutics's EPS at -$2.17 for the fiscal year ending Dec 31, 2026, on revenue of $100000.
What EPS do analysts expect from DRMA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.17, with estimates from -$2.17 to -$2.17 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.43, with estimates from -$1.43 to -$1.43 from 1 analyst.
What revenue do analysts expect from Dermata Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $100000, with estimates from $100000 to $100000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $750000, with estimates from $750000 to $750000.
How many analysts cover DRMA?
1 analyst estimates EPS for Dermata Therapeutics for the fiscal year ending Dec 31, 2026.
DRMA pages: Overview, Earnings, Forecast, Financials, Competitors